get.oc.tite.gBOIN: Obtain the operating characteristics of the Time-to-event...

Description Usage Arguments Details Value

View source: R/titegboin.R

Description

Obtain the operating characteristics of the Time-to-event gBOIN design for late-onset toxicity grades by simulating trials.

Usage

 1
 2
 3
 4
 5
 6
 7
 8
 9
10
11
12
13
14
15
get.oc.tite.gBOIN(
  target,
  prob,
  ncohort,
  cohortsize,
  maxt = 1,
  prior.p = NA,
  accrual = 3,
  maxpen = 0.5,
  alpha = 0.5,
  startdose = 1,
  cutoff.eli = 0.95,
  ntrial = 1000,
  seed = seed
)

Arguments

target

the target ETS

prob

a matrix containing the true toxicity probabilities of each grade x the investigational dose levels.

ncohort

the total number of cohorts

cohortsize

the cohort size

maxt

the maximum follow-up time

prior.p

a vector of length 3, which specifies the prior probability that the time to toxicity lies inside the time interval (0,maxt/3), (maxt/3,2maxt/3), (2maxt/3,1). The default value is prior.p=c(1/3,1/3,1/3).

accrual

the accrual rate, i.e., the number of patients accrued in 1 unit of time,

maxpen

the maximum proportion of pending patients

alpha

a number from (0,1) that controls alpha*100% events in (0, 1/2T). The default is alpha=0.5.

startdose

the starting dose level for the trial

cutoff.eli

the cutoff to eliminate an overly toxic dose for safety. We recommend the default value of (cutoff.eli=0.95) for general use.

ntrial

the total number of trials to be simulated.

seed

set seed

Details

This function generates he operating characteristics of the Time-To-Event Bayesian Optimal Interval design for toxicity grades(TITE-gBOIN) with delayed toxicities grades by simulating trials under the prespecified true ETS of the investigational doses.

Value

get.oc.tite.gBOIN() returns the operating characteristics of the TITE-gBOIN design as a data frame, including: (1) selection percentage at each dose level (selpercent), (2) the number of patients treated at each dose level (nptsdose), (3) the number of toxicities observed at each dose level (ntoxdose), (4) the average number of toxicities (totaltox), (5) the average number of patients (totaln), (6) the percentage of early stopping without selecting the MTD (pctearlystop). (7) the average trial duration needed for the trial based on the TITE-gBOIN design (duration) (8)the standard deviation of trial duration needed for the trial based on the TITE-gBOIN design (sdduration)


qingxiaa/titegboin documentation built on Dec. 22, 2021, 10:55 a.m.